CD40 and cancer: In our study, we found that aDEC205-OVA, administered with poly(I:C) and anti-CD40 adjuvants, was effective in generating anti-OVA responses in mice; however, whereas anti-CD40 antibodies (that target the costimulatory receptor CD40 on DCs to induce their maturation) are highly effective in mice, they have displayed severe toxicity in human cancer immunotherapy trials.48